Study to evaluate VNS Therapy for Treatment-Resistant Depression in accordance with agency’s National Coverage Determination as part of its Coverage with Evidence Development Program
“Now that the RECOVER study protocol has been finalized, we are ready to activate sites that will enroll patients in this important study. Those who suffer from depression that is difficult to treat may gain access through this study to a potentially life-altering treatment option,” said
RECOVER is a double-blind, randomized, placebo-controlled study with a follow-up duration of at least one year. The CED also includes the possibility to extend the study to a prospective longitudinal study. Enrollment is expected to begin in late 2019 and will include up to 500 unipolar and up to 500 bipolar patients at a maximum of 100 sites in
“In previous studies, we have seen VNS Therapy for TRD be highly effective and significantly improve response and remission rates when used as an adjunctive therapy,” said Dr.
More information about the protocol will be available at ClinicalTrials.gov.
The Company currently employs approximately 4,000 employees.
For more information, please visit www.livanova.com.
Safe Harbor Statement
This news release contains forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements are not historical facts but are based on certain assumptions of management and describe LivaNova’s future plans, strategies and expectations. Forward-looking statements can generally be identified by the use of forward-looking terminology, including, but not limited to, "may," “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements contained in this news release are based on information presently available to
All information in this news release is as of the date of its release.
LivaNova PLC Investor Relations and Media
Vice President, Investor Relations
Director, Corporate Communications